Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...

Gilead Sciences GILD underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their ...

International AIDS Society, an association of HIV/AIDS professionals, applauded moves by Gilead Sciences, a biopharma company, to make the generic injectable lenacapavir for HIV prevention widely ...

Oct 3 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical Supply for emergency use in ...

American biopharmaceutical company Gilead Sciences, on Thursday, October 3, announced that it will donate about 5,000 vials of its antiviral drug Remdesivir for emergency use in response to the ...